Covid-19 Delta surges shatter dreams of strong Q321 market recovery
Surges in COVID-19 Delta cases shattered any dreams of a strong Q321 Total Joints market recovery. Postponement of elective procedures in various areas of the US again negatively impacted Companies pushing out hopes for a return to normal into 2022. In addition to procedure recovery challenges, China’s Volume-Based Procurement program that aims to reduce implant pricing may headwind to the WW Total Joints market in the coming year.
Among the many topics covered in detail in our comprehensive Q321 Total Joints Market Recap* are:
- Complete Q321 Total Joints Market Overview and Highlights
- SmartTRAK's Expert Analysis and Insights
- Total Joints News including Revenues, Data, Charts and Shares
- US Market Growth Comparison Q321 vs Q319
- New Products Hitting the Stage
- Q321 Regulatory Highlights
Market leader Zimmer Biomet’s Q321 results validated early premonitions that COVID-19 Delta surges would depress procedure recovery. The Company reported its global Hip business declined compared to Q319 pre-COVID levels with the Knee business down comparably. In August, Zimmer Biomet generated positive buzz at the American Academy of Orthopedic Surgeons (AAOS) 2021 annual meeting with the introduction of the Persona IQ “smart knee”. However ...
*The entire unedited article and these links can only be viewed by SmartTRAK subscribers to this module. For more information on SmartTRAK, including how to receive a demo and subscribe, please click the button below.
SmartTRAK has recently expanded it's coverage to include five new modules, including Pediatric Extremities and Trauma. Click to see details of all the exciting new additions to the SmartTRAK platform in 2021.
